LAG3 and hepatocellular carcinoma: Cabolimab (TSR-022) is an anti-Tim-3 mAb, whose efficacy as a single agent and in combination with anti-PD1, anti LAG-3, or anti PD-L1 mAbs is under investigation in a multicenter, open-label, first-in-human study (NCT02817633) in patients with advanced solid tumors, including HCC [63].